Following on from earlier approvals in the US, the European Commission announced it has given marketing approval for both Gilead’s Yescarta and Novartis’s Kymriah for treatment of patients with various forms of blood cancer.

https://labiotech-eu.cdn.ampproject.org/c/s/labiotech.eu/medical/car-t-cell-therapy-europe/amp/